Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
KeyBanc Starts Castle Biosciences (CSTL) at Overweight
November 9, 2020 4:16 PM ESTKeyBanc initiates coverage on Castle Biosciences (NASDAQ: CSTL) with a Overweight rating and a price target of $70.00.
For an analyst ratings summary and ratings history on Castle Biosciences click here. For more ratings news on Castle Biosciences click here.
Shares of Castle Biosciences closed at $51.70 yesterday.
... More